ReviewZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
[Advances in intravesical therapy for non
Review in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BCa) is a common malignant tumor of the urinary system. Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed BCa cases. Transurethral resection of bladder tumor (TURBT) is currently the principal treatment for NMIBC; however, the postoperative recurrence rate remains high, making adjuvant pharmacological therapy an important component of treatment. In recent years, substantial advances have been made in pharmacological strategies for NMIBC, including immunotherapy, targeted therapy, and novel drug delivery systems. Immune checkpoint inhibitors (ICIs) have demonstrated definite efficacy in high-risk patients who are unresponsive to bacillus Calmette-Guérin. Antibody-drug conjugates (ADCs), such as RC-48, have shown favorable antitumor activity in selected patient populations. With regard to targeted therapy, erdafitinib has achieved breakthrough progress in patients with BCa harboring fibroblast growth factor receptor (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.